Free Trial
→ My top 3 AI picks for the next decade (From The Oxford Club) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$63.35
-3.7%		$74.14
$52.75
▼
$93.42
$12.37B0.972.89 million shs1.24 million shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$109.14
-1.7%		$106.78
$61.22
▼
$116.85
$12.38B0.881.93 million shs949,220 shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$15.66
-8.6%		$15.64
$12.07
▼
$29.23
$12.52B-1.514.61 million shs3.60 million shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$34.71
-3.1%		$53.04
$34.64
▼
$72.66
$3.35B0.61.39 million shs394,878 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+0.61%-0.59%-9.24%-21.81%+18.49%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
+0.60%+2.56%+3.62%+48.01%+73.29%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-2.62%-0.81%-2.39%+10.73%-19.77%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-1.73%-4.68%-38.94%-46.79%-9.66%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$63.35
-3.7%		$74.14
$52.75
▼
$93.42
$12.37B0.972.89 million shs1.24 million shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$109.14
-1.7%		$106.78
$61.22
▼
$116.85
$12.38B0.881.93 million shs949,220 shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$15.66
-8.6%		$15.64
$12.07
▼
$29.23
$12.52B-1.514.61 million shs3.60 million shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$34.71
-3.1%		$53.04
$34.64
▼
$72.66
$3.35B0.61.39 million shs394,878 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+0.61%-0.59%-9.24%-21.81%+18.49%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
+0.60%+2.56%+3.62%+48.01%+73.29%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-2.62%-0.81%-2.39%+10.73%-19.77%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-1.73%-4.68%-38.94%-46.79%-9.66%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.83
Moderate Buy$105.4264.90% Upside
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.67
Moderate Buy$94.00-14.39% Downside
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.53
Moderate Buy$28.6179.75% Upside
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
2.87
Moderate Buy$70.1499.43% Upside

Current Analyst Ratings Breakdown

Latest XENE, SMMT, BBIO, and HALO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetNeutral$70.00 ➝ $78.00
10/7/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$115.00 ➝ $130.00
10/7/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOverweight$157.00 ➝ $156.00
10/6/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
10/6/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$73.00
10/5/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
10/5/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
10/5/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingMarket Perform
10/5/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOverweight
10/2/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
10/1/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetEqual Weight$18.00 ➝ $20.00
(Data available from 10/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M24.89N/AN/A($10.77) per share-5.94
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.66B7.49$4.74 per share23.14$0.42 per share261.42
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/A$0.85 per shareN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$7.50M453.33N/AN/A$7.53 per share4.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.57N/AN/AN/A-97.03%N/A-61.19%10/28/2026 (Estimated)
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$316.89M$3.3532.9211.770.4224.86%260.98%23.91%11/2/2026 (Estimated)
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$1.08B-$1.12N/AN/AN/AN/A-168.94%-141.92%10/19/2026 (Estimated)
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$345.91M-$4.74N/AN/AN/AN/A-43.98%-41.72%11/2/2026 (Estimated)

Latest XENE, SMMT, BBIO, and HALO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/2/2026Q3 2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$2.28N/AN/AN/A$487.13 millionN/A
11/2/2026Q3 2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$1.13N/AN/AN/A$1.33 millionN/A
10/28/2026Q3 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5933N/AN/AN/A$273.56 millionN/A
10/19/2026Q3 2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.2806N/AN/AN/A$0.07 millionN/A
8/10/2026Q2 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5756-$0.78-$0.2044-$0.78$220.91 million$243.68 million
8/6/2026Q2 2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.79$2.28+$0.49$1.90$402.28 million$481.00 million
8/6/2026Q2 2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$1.16-$1.11+$0.05-$1.11$1.67 millionN/A
7/23/2026Q2 2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.2744-$0.28-$0.0056-$0.28$0.11 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
N/AN/AN/AN/AN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.23
1.17
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
13.50
2.71
2.31
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
6.96
6.96
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/A
21.01
21.02

Institutional Ownership

CompanyInstitutional Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
97.79%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
95.45%

Insider Ownership

CompanyInsider Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.50%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
83.50%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
2.91%
CompanyEmployeesShares OutstandingFree FloatOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
839195.49 million167.67 millionOptionable
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
423113.50 million110.66 millionOptionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
265799.73 million131.96 millionOptionable
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
36496.67 million93.85 millionOptionable

Recent News About These Companies

Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 12-Month Low - Here's Why
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-xenon-pharmaceuticals-nasdaq-xene-hits-new-12-month-low-heres-why-2026-10-13/
Xenon Pharmaceuticals (NASDAQ:XENE) Downgraded by Wall Street Zen to "Strong Sell"
October 11 at 1:07 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31106676
Xenon Pharmaceuticals (NASDAQ:XENE) Cut to "Strong Sell" at Wall Street Zen
October 11 at 1:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-xenon-pharmaceuticals-nasdaq-xene-cut-to-strong-sell-at-wall-street-zen-2026-10-11/
Why Xenon Pharmaceuticals (XENE) Is Getting Attention Now
October 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/why-xenon-pharmaceuticals-xene-getting-231010016.html
Xenon Pharmaceuticals (XENE) Stock May Still Look Above Fair Value On Its Research Pipeline
October 9, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/xenon-pharmaceuticals-xene-stock-may-141401053.html
Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
October 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/07/3376617/1453/en/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors.html
Xenon Pharmaceuticals (NASDAQ:XENE) Sets New 1-Year Low - Here's Why
October 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-xenon-pharmaceuticals-nasdaq-xene-sets-new-1-year-low-heres-why-2026-10-06/
Xenon Pharmaceuticals (NASDAQ:XENE) Given "Buy" Rating at Guggenheim
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31091629
Guggenheim Reaffirms "Buy" Rating for Xenon Pharmaceuticals (NASDAQ:XENE)
October 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-guggenheim-reaffirms-buy-rating-for-xenon-pharmaceuticals-nasdaq-xene-2026-10-06/
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 2, 2026
October 5, 2026  |  biospace.comB
Xenon CFO buys 15,000 shares
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31084186
Xenon Pharmaceuticals (NASDAQ:XENE) Stock: Insider Ian Mortimer Purchases 30,000 Shares
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31082446
Xenon Pharmaceuticals (NASDAQ:XENE) Stock: Insider Thomas Patrick Kelly Buys 15,000 Shares
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31082444
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Rating of "Moderate Buy" from Brokerages
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081952
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of "Moderate Buy" from Brokerages
October 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-xenon-pharmaceuticals-inc-nasdaq-xene-receives-average-recommendation-of-moderate-buy-from-brokerages-2026-10-03/
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Climb 5.2% After Insider Buying Activity
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081757
Wall Street Zen Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to "Sell"
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081512
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Lifted to "Sell" by Wall Street Zen
October 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-xenon-pharmaceuticals-nasdaq-xene-stock-lifted-to-sell-by-wall-street-zen-2026-10-03/
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026  |  financialpost.comF
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/02/3374010/33485/en/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Insider Buying: Xenon Pharmaceuticals (NASDAQ:XENE) CFO Buys $559,800.00 in Stock
October 2, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-xene-insider-buying-and-selling-2026-10-02/

New MarketBeat Followers Over Time

Media Sentiment Over Time

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$63.35 -2.40 (-3.65%)
As of 02:14 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Halozyme Therapeutics stock logo

Halozyme Therapeutics NASDAQ:HALO

$109.14 -1.94 (-1.74%)
As of 02:14 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$15.66 -1.48 (-8.61%)
As of 02:14 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Xenon Pharmaceuticals stock logo

Xenon Pharmaceuticals NASDAQ:XENE

$34.71 -1.10 (-3.08%)
As of 02:14 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas